Company intelligence / Profile preview
Energesis Pharmaceuticals
Cambridge, Massachusetts, United States
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Energesis has demonstrated animal proof of concept showing reductions in body weight, body fat, and blood sugar without loss of lean mass or changes in food intake, and is positioned to run a Phase 2 trial of its lead oral combination product EGS-2632 for obesity and metabolic disease.[1][6]
- Therapeutic areas
- EndocrinologyMetabolic Disorders
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Akston Biosciences (exclusive option and CDMO partnership for companion animal obesity BAT biologic therapy)[4]
Beyond the preview
Go deeper on Energesis Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Energesis Pharmaceuticals.